HIV prevention is a pathway to global health equity
Rights-based, people-centered, evidence-informed
Ending AIDS – and preparing for future pandemics – means developing truly effective prevention that meets people where they are and delivering it expeditiously and equitably. It requires a commitment to building a comprehensive, integrated, and sustained response.
podcast
In the days ahead under a new US Presidential Administration, advocacy for choice, freedom, science, and rights will require intentional strategies to protect hard fought gains in HIV treatment and prevention. And there will be major implications for the global AIDS response.
Blog Post
As we continue to grapple with the results of the US presidential election and what this means for our work and for global health evidence- and rights-based policies and programs generally, we wanted to share a range of new tools and resources you may find helpful in your advocacy for choice, science and rights.
Blog Post
We will all need time to process the US election results and strategize how we navigate through them in the years ahead — as individuals, as a network of partners, and as advocates for choice, science, and rights. We look forward to working with our partners in protecting hard-fought gains and assessing the potential impact on PEPFAR, Global Fund support, and on US government aid agencies.
Advocacy, communication, data and policy analysis, education
We leverage global partnerships to accelerate ethical development and equitable delivery of effective HIV prevention options, as part of a comprehensive and integrated pathway to global health equity.
We work with partners to develop and pursue bold national, regional, and international agendas that advance HIV prevention and global health equity and lay a solid foundation for global health security against future pandemics.
Learn more
We invest in efforts to understand potential users of prevention products, compile and analyze market data, and convene decision-makers in conversation to more effectively design products and programs that increase access to prevention options that people want and need.
Learn more
We prioritize skills-sharing and knowledge-exchange among communities, advocates, civil society, researchers, donors, policy-makers and other stakeholders, and work to cultivate and sustain dynamic partnerships that set bold and innovative agendas for HIV prevention and health equity.
Learn more
We track and translate complex science, funding and policy decisions, community advocacy and more, to make it accessible, provide context, identify gaps and opportunities for advocacy and ensure community priorities are at the center of global health.
Learn more
We champion the Good Participatory Guidelines and connect decision-makers to a network of research-savvy advocates prioritizing community voices and bring accountability to prevention science and policy.
Learn more
The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.